|Bid||442.26 x 900|
|Ask||467.64 x 1100|
|Day's Range||442.23 - 457.57|
|52 Week Range||260.42 - 555.77|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||106.39|
|Earnings Date||Aug 04, 2021 - Aug 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||410.18|
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
EU antitrust regulators will rule by July 27 whether to clear Illumina Inc's proposed $7.1 billion acquisition of cancer test maker Grail Inc , a European Commission filing showed on Thursday. U.S. life sciences company Illumina, which is also challenging the EU watchdog's decision to review the deal even though it does not meet the EU revenue criteria, filed for EU approval on Wednesday. The company has said it will pursue a dual-track tactic, launching litigation against the Commission while following the EU merger process.
In 2016, Cathie Wood and ARK investment management described Illumina (NASDAQ: ILMN) as "the cornerstone of our Genomic Revolution theme, and one of our highest conviction stocks." Illumina became one of the largest holdings across several ARK ETFs including the ARK Innovation ETF (NYSEMKT: ARKK) and ARK Genomic Revolution ETF (NYSEMKT: ARKG). What was behind ARK's loss of conviction in Illumina?